Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
We aimed to review the evidence of reducing the dose or number of BCG instillations in non-muscle invasive bladder cancer (NMIBC) patients. A literature search was done according to Preferred Reporting Items for Meta-Analyses statement. Overall, 15 and 13 studies were eligible for qualitative and quantitative synthesis, respectively. In patients with NMIBC, lowering either the dose or number of BCG instillations increases the risk of recurrence, but not the risk of progression. Lowering the dose of BCG decreases the risk of adverse events compared with standard-dose BCG. Standard-dose and -number of BCG is preferred for NMIBC patients based on oncologic efficacy; however, low-dose BCG could be considered in selected patients who suffer from significant adverse events.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/imt-2022-0309 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk factors and leprosy incidence among contacts in Bangladesh: A multilevel analysis.
PLoS Negl Trop Dis
September 2025
Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Background: The Maltalep trial in Bangladesh assessed whether single-dose rifampicin (SDR) given 8-12 weeks after bacillus Calmette-Guérin (BCG) vaccination was able to prevent excess leprosy cases due to BCG in contacts of newly diagnosed leprosy patients. After previous publication of the two years follow-up results of the trial, we now review the results after five years. Furthermore, to better understand the long-term protective effects of BCG against leprosy, we conduct post-hoc in-depth secondary statistical analyses based on the prospective interventional (randomized) Maltalep trial and a non-interventional (non-randomized) cohort study that was conducted simultaneously in the same project area.
View Article and Find Full Text PDFOutcome and Impact of Diagnostic Ureteroscopy in Clinically Suspected Upper Urinary Tract Carcinoma .
J Endourol
September 2025
Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
To clarify disease behavior and oncological outcomes as well as the need for ureteroscopy (URS) implementation in patients with clinically suspected upper tract carcinoma (UT-CIS). In this multi-institutional study, we retrospectively analyzed patients who met three criteria for clinically suspected UT-CIS between 2008 and 2018: positive high-grade cytology from the upper tract, absence of a solid upper tract lesion on imaging, and negative bladder biopsy. Patients who underwent URS were compared with those who did not.
View Article and Find Full Text PDFBCG Impact on PD-1/PD-L1 Expression in Peripheral Immunocytes of Cancer Patients-A Potential Explanation for Its Activity in Preventing Alzheimer's Disease.
Curr Issues Mol Biol
August 2025
Department of Microbiology and Molecular Genetics, Hebrew University Medical School, Jerusalem 9112102, Israel.
We found, retrospectively, that BCG therapy in non-muscle invasive bladder cancer (NMIBC) reduces the rate of Alzheimer's disease. Blockade of the ligand PD-L1 or its checkpoint receptor PD-1 has been shown to improve cognitive function and reduce brain pathology features in a mouse model of Alzheimer's disease (AD). Given that peripheral blood mononuclear cells (PBMCs) are involved in aging brain pathology and thus represent a potential AD therapeutic target, we analyzed the impact of BCG on the expression of PD-1, PD-L1, and inflammation modulators in PBMCs.
View Article and Find Full Text PDFThe value of maintenance therapy in intermediate-risk non-muscle-invasive bladder cancer.
BJU Int
August 2025
Division of Experimental Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
Objective: To evaluate which subgroups of patients with intermediate-risk non-muscle-invasive bladder cancer (IR-NMIBC) benefit from maintenance therapy based on the International Bladder Cancer Group (IBCG) risk stratification, as the role of a maintenance course in patients with IR-NMIBC is debated.
Patients And Methods: We relied on a prospectively maintained database of patients with IR-NMIBC who received intravesical chemotherapy or Bacillus Calmette-Guérin (BCG) (2010-2023). Patients were stratified according the IBCG prognostic algorithm (no, one to two, and three or more risk factors).
MDSC depletion during immunization with heat-killed increases protection against BCG infection.
Front Immunol
August 2025
Institute for Virology and Immunobiology, University of Würzburg, Würzburg, Germany.
Tuberculosis (TB) remains one of the deadliest infectious diseases globally. Although the approved human Bacille-Calmette-Guérin (BCG) vaccines provide limited protection, a vaccine based on (Mtb) has yet to be approved. Our previous findings demonstrated that s.
View Article and Find Full Text PDF